NASDAQ: QDEL · Medical Specialties

QuidelOrtho (QDEL) fair value and price range

As of 16 Nov 2026, Faircurve's model values QuidelOrtho (QDEL) at $15.28 a share. The stock last closed at $10.21, which puts the model's fair value 49.7% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

Revalued . Price is the close of 16 Nov 2026. QuidelOrtho Corporation.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$15.28midpoint of 2,000 simulations
Last close$10.21NASDAQ: QDEL
Gap to fair value+49.7%fair value against price
Model verdictLow evidence gradeevidence grade: Low

This week, in three parts

What happenedThe run of 16 Nov 2026 moved the fair value from $14.63 to $15.28 (+4.4%).

What the model makes of itThe price of $10.21 is 49.7% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

What's nextNext report on 10 Feb 2027. Options prices imply a move of about 26% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give QDEL?

The calibrated range for QDEL over 63 trading days is $7.57 to $13.97. It sits around the last close, and its width comes from the volatility that QDEL's own options imply (90% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $0.74 to $33.98. In 59% of the simulations the fair value came out above the price the model ran on.

Faircurve Insights · 16 Nov 2026

QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units.

On 16 Nov 2026, Faircurve's model put the fair value of QuidelOrtho Corporation (QDEL) at $15.28 a share, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $14.63, so the fair value moved +4.4%. The calibrated range over 63 trading days is $7.97 to $14.70. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.

QuidelOrtho scores 27 out of 100 on the model's overall quality measure, a composite of six factors scored against peers. Earnings quality stands out at 92, while profitability scores 0, with ROIC at -2.6% against a peer median of 7.2%. Growth quality scores 15, with trailing revenue growth at -1.9% against a peer median of 14.3%. The model compares the company with STERIS plc (STE), Cytek Biosciences, Inc. (CTKB), HealthStream, Inc. (HSTM), Artivion, Inc. (AORT) and Integra LifeSciences Holdings Corporation (IART).

Written from the figures on this page for the 16 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does QDEL report earnings, and how has the stock reacted?

QuidelOrtho's next earnings report is scheduled for 10 Feb 2027. Companies can move their dates.

On 16 Nov 2026, QDEL's 30 day implied volatility worked out to a move of about 26.1% over one month, in either direction. That is a size, not a direction.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across QDEL's last 8 reports, ignoring direction, was 10.3%.

0%10%20%30%13.8%0.4%12 Feb '2516.1%2.8%5 Aug '25no quote21.6%5 Nov '25no quote18.7%11 Feb '26no quote11.8%5 May '26no quote29.8%6 Aug '2626.6%2.3%3 Nov '2629.0%8.9%4 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in QDEL

10%15%20%25%30%35%40%45%4 Nov '26 report3 Nov '26 report6 Aug '26 report5 May '26 report11 Feb '26 report26% at 12 Nov '2612 Nov '2512 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 20% on 12 Nov 2025, reached 41% on 30 Oct 2026 and reads 26% on 12 Nov 2026. The marks are report dates.

How does QDEL score on business quality?

QuidelOrtho's overall quality score is 27 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.0-2.6%ROIC7.2%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).92
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.15-1.9%Revenue growth, trailing14.3%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.580.0%Net buybacks / market value0.0%
Balance sheetNet debt to EBITDA and interest coverage.19.02xNet debt / EBITDA
StabilityDownside volatility of the EBITDA margin over the last five years.029.7 ptsEBITDA margin downside volatility, 5y1.5 pts

How does QDEL compare with similar companies?

The companies in medical specialties closest to QuidelOrtho in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
STE STERIS plc$261.91$251.44-4.0%Fairly valued
CTKB Cytek Biosciences, Inc.$5.63$6.03+7.1%Fairly valued
COLL Collegium Pharmaceutical, Inc.$25.43$25.54+0.4%Low evidence grade
HSTM HealthStream, Inc.$27.68$27.45-0.8%Fairly valued
AORT Artivion, Inc.$18.47$20.28+9.8%Fairly valued
AHCO AdaptHealth Corp.$7.73$7.47-3.4%Low evidence grade
IART Integra LifeSciences Holdings Corporation$13.98$16.00+14.4%Fairly valued
AMPH Amphastar Pharmaceuticals, Inc.$29.17$29.56+1.3%Low evidence grade

What the comparable companies' multiples alone would give for QDEL, the peer-implied price, is $40.47 a share on this run. The fair value weighs that against the company's own multiple.

All healthcare stocks ranked by gap to fair value

QuidelOrtho at a glance

QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units.

Market value
$737M
Sector
Healthcare
Industry
Medical Specialties
Revenue expected, next twelve months
$2.5B
Consensus revenue growth, next fiscal year
-7.7%
Analysts with estimates
1
Beta to the US market
2.53
First valued by Faircurve
11 Jul 2026

How the fair value is worked out: the model prices QuidelOrtho on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for QDEL was $14.63. As of 16 Nov 2026 it is $15.28, a change of +4.4%. The model revalues every stock it covers each week, and again after an earnings report.

Questions about QuidelOrtho's valuation

Is QuidelOrtho stock undervalued or overvalued?

Faircurve's model puts QDEL's fair value at $15.28 a share against a last close of $10.21, as of 16 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

What is QDEL's fair value?

$15.28 a share as of 16 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $0.74 to $33.98.

What price range does the model give QDEL?

$7.57 to $13.97 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does QuidelOrtho report earnings next?

The next report is scheduled for 10 Feb 2027. Companies can move their dates.

How much has QDEL moved on past earnings reports?

Across its last 8 reports the median two session move was 10.3%, ignoring direction. The largest was -29.8% around the report of 6 Aug 2026.

How confident is the model in this valuation?

The model's evidence grade for QDEL is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on QDEL

The model holds no idea open on QDEL today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on QDEL with their outcomes. A free account is enough.

Keep reading